DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil
Figure 2
(a) Overall survival in a followup of 120 months with an estimated probability of overall survival of 41.7%; (b) disease-free survival in a followup of 120 months with an estimated probability of disease-free survival of 23.4%.
